Patients in tocilizumab treatment group 4 times more likely to see remission.
One of the most feared symptoms of giant cell arteritis - the most common form of vasculitis afecting patients 50 years and older - is visual loss. At the Annual Meeting of the Association for Research in Vision and Ophthalmology, Genentech's Christine Birchwood presented findings of the use of tocilizumab in the treatment of giant cell arteritis.
Genentech's tocilizumab is an anti-interleukin-6 inhibitor. It is currently approved for the treatment of adults with rheumatoid arthritis and patients with systemic juvenile arthritis.